From bombs to bro­mides? Trump’s joust­ing with bio­phar­ma may well boil down to a hand­shake on drug prices

A few months ago, the prospect of an ex­ec­u­tive or­der from Pres­i­dent Don­ald Trump on drug pric­ing would have been the cause of high anx­i­ety in bio­phar­ma. Af­ter all, Trump set­tled in­to the White House loud­ly com­plain­ing of just how bad­ly the drug in­dus­try has been rip­ping off the Amer­i­can pub­lic.

Now there are a va­ri­ety of re­ports that an EO is com­ing — and the in­dus­try could be in for a mid-year boost if in fact Trump does as ex­pect­ed and keeps the di­rec­tive lim­it­ed in scope and im­pact.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.